India’s CDSCO Drafts Compensation Formula For Clinical Trial Participants
This article was originally published in PharmAsia News
India’s agency for drug standards said it has developed a formula for figuring the compensation pharmaceutical companies must make to injured trial participants or families of those who died as a result of the tests.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.